inTEST Reports Revenue Up 36% Year-over-Year to Record $29.6 Million for Second Quarter 2022

A telephonic replay will be available from 7:45 p.m. ET on the day of the call through Thursday August 11, 2022. To listen to the archived call, dial (412) 317-6671 and enter replay pin number 22019594 or access the webcast replay via the Company’s website. A transcript will also be posted to the website once available.

About inTEST Corporation

inTEST Corporation is a global supplier of innovative test and process solutions for use in manufacturing and testing in key target markets which include automotive, defense/aerospace, industrial, life sciences, and security, as well as both the front-end and back-end of the semiconductor manufacturing industry. Backed by decades of engineering expertise and a culture of operational excellence, inTEST solves difficult thermal, mechanical, and electronic challenges for customers worldwide while generating strong cash flow and profits. inTEST’s strategy leverages these strengths to grow organically and with acquisitions through the addition of innovative technologies, deeper and broader geographic reach, and market expansion. For more information, visit www.intest.com.

Non-GAAP Financial Measures

In addition to disclosing results that are determined in accordance with GAAP, we also disclose non-GAAP financial measures. These non-GAAP financial measures consist of adjusted net earnings (loss), adjusted earnings (loss) per diluted share, adjusted EBITDA, and adjusted EBITDA margin. Adjusted net earnings (loss) is derived by adding acquired intangible amortization, adjusted for the related income tax expense (benefit), to net earnings (loss). Adjusted earnings (loss) per diluted share is derived by dividing adjusted net earnings (loss) by diluted weighted average shares outstanding. Adjusted EBITDA is derived by adding acquired intangible amortization, interest expense, income tax expense, depreciation, and stock-based compensation expense to net earnings (loss). Adjusted EBITDA margin is derived by dividing adjusted EBITDA by revenue. These results are provided as a complement to the results provided in accordance with GAAP. Adjusted net earnings (loss) and adjusted earnings (loss) per diluted share are non-GAAP financial measures presented to provide investors with meaningful, supplemental information regarding our baseline performance before acquired intangible amortization charges as this expense may not be indicative of our underlying operating performance. Adjusted EBITDA and adjusted EBITDA margin are non-GAAP financial measures presented primarily as a measure of liquidity as they exclude non-cash charges for acquired intangible amortization, depreciation and stock-based compensation. In addition, adjusted EBITDA and adjusted EBITDA margin also exclude the impact of interest income or expense and income tax expense or benefit, as these expenses may not be indicative of our underlying operating performance. The non-GAAP financial measures presented in this press release are used by management to make operational decisions, to forecast future operational results, and for comparison with our business plan, historical operating results and the operating results of our peers. Reconciliations from net earnings (loss) and earnings (loss) per diluted share to adjusted net earnings (loss) and adjusted earnings (loss) per diluted share and from net earnings (loss) to adjusted EBITDA and adjusted EBITDA margin, are contained in the tables below. The non-GAAP financial measures discussed in this press release may not be comparable to similarly titled measures used by other companies. The presentation of non-GAAP financial measures is not meant to be considered in isolation, as a substitute for, or superior to, financial measures or information provided in accordance with GAAP.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements do not convey historical information but relate to predicted or potential future events and financial results, such as statements of the Company’s plans, strategies and intentions, or our future performance or goals, that are based upon management's current expectations. These forward-looking statements can often be identified by the use of forward-looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” “plans,” “projects,” “forecasts,” “outlook,” “anticipates,” “targets,” “estimates,” or similar terminology. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Such risks and uncertainties include, but are not limited to, any mentioned in this press release as well as the Company’s ability to execute on its 5-Point Strategy, realize the potential benefits of acquisitions and successfully integrate any acquired operations, grow the Company’s presence in the life sciences, security, industrial and international markets, manage supply chain challenges, convert backlog to sales and to ship product in a timely manner; the success of the Company’s strategy to diversify its markets; the impact of inflation on the Company’s business and financial condition; the impact of the COVID-19 pandemic on the Company’s business, liquidity, financial condition and results of operations; indications of a change in the market cycles in the semi market or other markets served; changes in business conditions and general economic conditions both domestically and globally; changes in the demand for semiconductors; the ability to borrow funds or raise capital to finance potential acquisitions or for working capital; changes in the rates and timing of capital expenditures by the Company’s customers; and other risk factors set forth from time to time in the Company’s Securities and Exchange Commission filings, including, but not limited to, the Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by the Company in this press release is based only on information currently available to management and speaks to circumstances only as of the date on which it is made. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

– FINANCIAL TABLES FOLLOW –

 

inTEST CORPORATION
Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

29,571

 

 

$

21,820

 

 

$

53,652

 

 

$

41,376

 

Cost of revenue

 

 

16,023

 

 

 

10,858

 

 

 

29,091

 

 

 

20,893

 

Gross profit

 

 

13,548

 

 

 

10,962

 

 

 

24,561

 

 

 

20,483

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling expense

 

 

4,033

 

 

 

2,605

 

 

 

7,489

 

 

 

5,008

 

Engineering and product development expense

 

 

1,859

 

 

 

1,356

 

 

 

3,783

 

 

 

2,678

 

General and administrative expense

 

 

4,928

 

 

 

3,769

 

 

 

9,759

 

 

 

6,930

 

Restructuring and other charges

 

 

-

 

 

 

197

 

 

 

-

 

 

 

252

 

Total operating expenses

 

 

10,820

 

 

 

7,927

 

 

 

21,031

 

 

 

14,868

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

2,728

 

 

 

3,035

 

 

3,530

 

 

5,615

Other income (expense)

 

 

(158

)

 

 

21

 

 

(305

)

 

 

19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings before income tax expense

 

 

2,570

 

 

 

3,056

 

 

3,225

 

 

5,634

Income tax expense

 

 

454

 

 

 

447

 

 

532

 

 

813

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings

 

$

2,116

 

 

$

2,609

 

$

2,693

 

$

4,821

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per common share - basic

 

$

0.20

 

 

$

0.25

 

$

0.25

 

$

0.46

Weighted average common shares outstanding - basic

 

 

10,653,268

 

 

 

10,442,916

 

 

 

10,635,270

 

 

 

10,386,183

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per common share - diluted

 

$

0.20

 

 

$

0.24

 

$

0.25

 

$

0.45

Weighted average common shares and common share equivalents outstanding - diluted

 

 

10,814,799

 

 

 

10,764,936

 

 

 

10,828,696

 

 

 

10,645,381

 

 

inTEST CORPORATION
Consolidated Balance Sheets
(In thousands)

 

 

 

June 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

ASSETS

 

(Unaudited)

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

10,543

 

 

$

21,195

 

Short term investments

 

 

3,485

 

 

 

-

 

Trade accounts receivable, net of allowance for doubtful accounts of $210 and $213, respectively

 

 

22,489

 

 

 

16,536

 

Inventories

 

 

17,519

 

 

 

12,863

 

Prepaid expenses and other current assets

 

 

1,550

 

 

 

1,483

 

Total current assets

 

 

55,586

 

 

 

52,077

 

Property and equipment:

 

 

 

 

 

 

 

 

Machinery and equipment

 

 

6,076

 

 

 

5,733

 

Leasehold improvements

 

 

3,206

 

 

 

3,001

 

Gross property and equipment

 

 

9,282

 

 

 

8,734

 

Less: accumulated depreciation

 

 

(6,324

)

 

 

(6,046

)

Net property and equipment

 

 

2,958

 

 

 

2,688

 

Right-of-use assets, net

 

 

5,320

 

 

 

5,919

 

Goodwill

 

 

21,720

 

 

 

21,448

 

Intangible assets, net

 

 

19,907

 

 

 

21,634

 

Restricted certificates of deposit

 

 

100

 

 

 

100

 

Other assets

 

 

434

 

 

 

39

 

Total assets

 

$

106,025

 

 

$

103,905

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Current portion of Term Note

 

$

4,100

 

 

$

4,100

 

Current portion of operating lease liabilities

 

 

1,419

 

 

 

1,371

 

Accounts payable

 

 

7,802

 

 

 

4,281

 

Accrued wages and benefits

 

 

3,090

 

 

 

4,080

 

Accrued professional fees

 

 

573

 

 

 

1,048

 

Customer deposits and deferred revenue

 

 

5,701

 

 

 

6,038

 

Accrued sales commissions

 

 

1,077

 

 

 

863

 

Domestic and foreign income taxes payable

 

 

1,536

 

 

 

2,024

 

Other current liabilities

 

 

1,598

 

 

 

1,267

 

Total current liabilities

 

 

26,896

 

 

 

25,072

 

Operating lease liabilities, net of current portion

 

 

4,539

 

 

 

5,248

 

Term Note, net of current portion

 

 

14,092

 

 

 

16,000

 

Deferred tax liabilities

 

 

574

 

 

 

1,379

 

Contingent consideration

 

 

1,330

 

 

 

930

 

Other liabilities

 

 

474

 

 

 

453

 

Total liabilities

 

 

47,905

 

 

 

49,082

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.01 par value; 5,000,000 shares authorized; no shares issued or outstanding

 

 

-

 

 

 

-

 

Common stock, $0.01 par value; 20,000,000 shares authorized; 11,048,708 and 10,910,460 shares issued, respectively

 

 

110

 

 

 

109

 

Additional paid-in capital

 

 

30,974

 

 

 

29,931

 

Retained earnings

 

 

27,086

 

 

 

24,393

 

Accumulated other comprehensive earnings

 

 

164

 

 

 

594

 

Treasury stock, at cost; 34,308 and 33,077 shares, respectively

 

 

(214

)

 

 

(204

)

Total stockholders' equity

 

 

58,120

 

 

 

54,823

 

Total liabilities and stockholders' equity

 

$

106,025

 

 

$

103,905

 

 

inTEST CORPORATION
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

 

 

 

Six Months Ended
June 30,

 

 

 

2022

 

 

2021

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

Net earnings

 

$

2,693

 

 

$

4,821

 

Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

2,528

 

 

 

1,461

 

Provision for excess and obsolete inventory

 

 

230

 

 

 

93

 

Foreign exchange loss

 

 

98

 

 

 

4

 

Amortization of deferred compensation related to stock-based awards

 

 

923

 

 

 

723

 

Loss on disposal of property and equipment

 

 

61

 

 

 

13

 

Deferred income tax benefit

 

 

(805

)

 

 

(81

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Trade accounts receivable

 

 

(6,607

)

 

 

(4,419

)

Inventories

 

 

(4,894

)

 

 

(1,326

)

Prepaid expenses and other current assets

 

 

(87

)

 

 

246

Restricted certificates of deposit

 

 

-

 

 

 

40

 

Other assets

 

 

(395

)

 

 

(6

)

Operating lease liabilities

 

 

(701

)

 

 

(641

)

Accounts payable

 

 

3,506

 

 

1,105

 

Accrued wages and benefits

 

 

(981

)

 

 

663

 

Accrued professional fees

 

 

(471

)

 

 

(72

)

Customer deposits and deferred revenue

 

 

(264

)

 

 

499

 

Accrued sales commissions

 

 

219

 

 

399

 

Domestic and foreign income taxes payable

 

 

(477

)

 

 

284

 

Other current liabilities

 

 

264

 

 

 

63

Other liabilities

 

 

61

 

 

 

(7

)

Net cash provided by (used in) operating activities

 

 

(5,099

)

 

 

3,862

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Refund of final working capital adjustment related to Acculogic

 

 

371

 

 

-

Purchase of property and equipment

 

 

(708

)

 

 

(463

)

Purchase of short-term investments

 

 

(3,477

)

 

 

-

 

Net cash used in investing activities

 

 

(3,814

)

 

 

(463

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Repayments of Term Note

 

 

(1,908

)

 

 

-

 

Proceeds from stock options exercised

 

 

-

 

 

 

1,002

 

Proceeds from shares sold under Employee Stock Purchase Plan

 

 

121

 

 

 

-

 

Shares redeemed into treasury stock

 

 

(10

)

 

 

-

 

Net cash provided by (used in) financing activities

 

 

(1,797

)

 

 

1,002

 

 

 

 

 

 

 

 

 

 

Effects of exchange rates on cash

 

 

58

 

 

(53

)

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) all activities

 

 

(10,652

)

 

 

4,348

Cash and cash equivalents at beginning of period

 

 

21,195

 

 

 

10,277

 

Cash and cash equivalents at end of period

 

$

10,543

 

 

$

14,625

 

 

 

 

 

 

 

 

 

 

Cash payments for:

 

 

 

 

 

 

 

 

Domestic and foreign income taxes

 

$

1,865

 

 

$

610

 

 

 

 

 

 

 

 

 

inTEST CORPORATION

Revenue by Market
(In thousands)
(Unaudited)

 

($ in 000s)

Three Months Ended

Change

Change

6/30/2022

3/31/2022

$

%

6/30/2021

$

%

Revenue

Semi

16,409

55.5%

13,390

55.6%

3,019

22.5%

15,677

71.8%

732

4.7%

Industrial

2,930

9.9%

2,799

11.6%

131

4.7%

1,524

7.0%

1,406

92.3%

Auto/EV

3,594

12.2%

2,756

11.5%

838

30.4%

842

3.9%

2,752

326.8%

Life Sciences

1,169

3.9%

699

2.9%

470

67.2%

586

2.7%

583

99.5%

Defense/Aerospace

1,423

4.8%

1,493

6.2%

(70)

-4.7%

1,522

7.0%

(99)

-6.5%

Security

794

2.7%

574

2.4%

220

38.3%

-

0.0%

794

NM

Other

3,252

11.0%

2,370

9.8%

882

37.2%

1,669

7.6%

1,583

94.8%

29,571

100.0%

24,081

100.0%

5,490

22.8%

21,820

100.00%

7,751

35.5%

 

« Previous Page 1 | 2 | 3 | 4 | 5 | 6  Next Page »



© 2024 Internet Business Systems, Inc.
670 Aberdeen Way, Milpitas, CA 95035
+1 (408) 882-6554 — Contact Us
ShareCG™ is a trademark of Internet Business Systems, Inc.

Report a Bug Report Abuse Make a Suggestion About Privacy Policy Contact Us User Agreement Advertise